NCT00803842撤回不适用
Evaluation of Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 主要终点
- The primary objective of this study is to determine whether administration of doxycycline affects erlotinib PK
研究概览
简要总结
A side effect occurring in a majority of patients taking erlotinib (Tarceva®) consists of a skin rash. Sometimes, symptoms associated with the rash necessitate erlotinib dose reduction or discontinuation. Some physicians have successfully treated the erlotinib-induced rash with doxycycline. At the same time, it has been observed that in patients who develop the erlotinib rash, the cancers respond better to erlotinib treatment. This research study is designed to determine how well doxycycline treats the erlotinib rash and whether doxycycline affects the blood levels of erlotinib.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 18 years of age or older.
- •Subjects must have started Tarceva® therapy within three (3) days of trial enrollment.
- •Patients must have signed informed consent prior to registration on study.
- •Currently receiving erlotinib therapy at 150 mg per day for locally advanced or metastatic NSCLC.
- •Patients - both males and females - with reproductive potential (ie, menopausal for less than 1 year and not surgically sterilized) must utilize barrier methods in combination with spermicidal agents for contraception when engaging in sexual intercourse. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.
排除标准
- •Allergy to tetracyclines.
- •Use of concurrent agents for papulopustular rash.
- •Currently receiving anticancer agents other than erlotinib.
- •Inability to interrupt other antibiotic therapy.
- •Current use of topical steroids
- •Current use of systemic immunosuppressants (e.g., methotrexate, cyclosporine, azathioprine, mycophenolate mofetil)
- •Photosensitivity or lupus erythematosus.
- •Active gastroesophageal reflux disease.
- •Women who have a positive pregnancy test or are lactating by history.
- •ECOG performance status ≤
- •Self report of current smoking or history of smoking within 60 days of screening, or positive urine cotinine test.
- •Current use of agents that are known to be strong inducers or inhibitors of CYTP3A4:
- •inhibitors: atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfi navir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), voriconazole, grapefruit or grapefruit juice
- •inducers: rifampicin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, and St. John's Wort
- •Impaired hepatic function (≤ 30 days before randomization):
- •Alkaline phosphatase > 3x ULN
- •Aspartate aminotransferase (AST) > x ULN
- •Alanine aminotransferase (ALT) > 3 x ULN
- •Total Bilirubin > 1.5 x ULN
结局指标
主要结局
The primary objective of this study is to determine whether administration of doxycycline affects erlotinib PK
时间窗: 14 days
次要结局
- Secondarily, this study aims to investigate the relationship between erlotinib AUC and rash severity and to evaluate the efficacy of doxycycline in rash management.(14 days)
研究者
相似试验
进行中（未招募）
不适用
A study of erlotinib (Tarceva®) treatment in patients with locally advanced or metastatic non-small cell lunf cancer who present activating mutations in the tyrosine kinase domain of the epidermal growth factor receptorocally advanced or metastatic non-small cell lung cancer with activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor.MedDRA version: 14.0Level: LLTClassification code 10025054Term: Lung cancer non-small cell stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023869-21-FIRoche Oy
进行中（未招募）
不适用
Pharmacodynamic study of Erlotinib (Tarceva) in patients with mestastatic or locally advanced Epidermoid carcinoma of the head and neckMestastatic or locally advanced Epidermoid carcinoma of the head and neckEUCTR2005-003814-14-ESnidad Integral de Investigación en Oncología, S.L.49
已完成
不适用
An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung CancerNon-Squamous Non-Small Cell Lung CancerNCT01194050Hoffmann-La Roche289
进行中（未招募）
不适用
A parallel phase II study of Tarceva (Erlotinib) in patients with advanced non-small cell lung cancer (Stage IIIB/IV) non pre-treated by chemotherapy including dose escalation to toxicity in current and former smokers. - NDPatients with advanced NSCLC not previously treated with chemotherapyMedDRA version: 6.1Level: PTClassification code 10029521EUCTR2005-004782-41-ITROCHE44
进行中（未招募）
1 期
Phase I study of TARCEVA (Erlotinib Hydrochloride, OSI-774) as a single agent in children with refractory and relapsed malignant brain tumours and in combination with irradiation in newly diagnosed brain stem glioma. - Tarceva in paediatric brain tumoursRefractory and relapsed malignant brain tumours and newly diagnosed brain stem glioma.EUCTR2004-005247-10-GBThe University Hospitals of Leicester NHS Trust48